articleJournal of Clinical OncologyApr 17, 2023Closed access

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

NJNicholas J. VogelzangJJJames J. RusthovenJTJames T. SymanowskiCDClaude DenhamEKE. Kaukel

Eli Lilly (United States) · Heidelberg University · +6 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with pemetrexed and cisplatin results in survival time superior to that achieved with cisplatin alone. PATIENTS AND METHODS Chemotherapy-naive patients who were not eligible for curative surgery were randomly assigned to receive pemetrexed 500 mg/m 2 and cisplatin 75 mg/m 2 on day 1, or cisplatin 75 mg/m 2 on day 1. Both regimens were given intravenously every 21 days. RESULTS A total of 456 patients were assigned: 226 received pemetrexed and cisplatin, 222 received…

Citation impact

253
total citations
FWCI
13.02
Percentile
100%
References
0
Citations per year

Authors

12

Topics & keywords

Topics
Keywords
  • Pemetrexed
  • Medicine
  • Cisplatin
  • Mesothelioma
  • Chemotherapy
  • Internal medicine
  • Oncology
  • Surgery
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.